News | September 24, 2021
Amaris Clinicals clears U.S. FDA audit
The company is the Clinical Research Organisation of Caplin Point Laboratories
The company is the Clinical Research Organisation of Caplin Point Laboratories
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
The approval will enable the treatment of patients in India living with Essential tremor, tremor-dominant Parkinson's Disease and neuropathic pain
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
Barbara Engelhardt moves her computational and statistics lab to Gladstone
Klifovet’s client base comprises the world’s top animal health and nutrition companies as well as many promising startups
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
This test can be run on commonly available qPCR cyclers, thereby, bypassing the need to perform expensive and time-consuming Next-Generation Sequencing
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
Subscribe To Our Newsletter & Stay Updated
